Fadraciclib

DB15425InvestigationalSmall molecule

CYC-065 is under investigation in clinical trial NCT03739554 (CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL).

Chemical structure of Fadraciclib
Formula / weight
C21H31N7O · 397.527 g/mol (avg)
Code names
CYC-065

Resolves to

Compound
UNIIYET2XNU791CAS1070790-89-4ChEMBLCHEMBL3655762
Structure
InChIKeyDLPIYBKBHMZCJI-WBVHZDCISA-NSMILESCC[C@H](NC1=NC(NCC2=C(C)C=C(C)N=C2)=C2N=CN(C(C)C)C2=N1)[C@@H](C)O
Targets
P24941CDK2P50750CDK9

What you can answer from here — as of October 27, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
7Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Fadraciclib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In